Biotechnology company Calidi Biotherapeutics has made significant progress in developing a novel systemic antitumor virotherapy platform designed to target metastatic cancers. The company announced the selection of an IL15 superagonist as the initial therapeutic payload for its RTNova platform, revealing promising preclinical research at the American Association for Cancer Research (AACR) Annual Meeting.
The innovative platform centers on an engineered vaccinia virus capable of delivering the IL15 superagonist (IL15-IL15Ra) directly into the tumor microenvironment. Preclinical data demonstrate that this approach can significantly boost immune response and tumor elimination while minimizing systemic toxicity, representing a potential breakthrough in cancer treatment strategies.
The RTNova platform aims to address critical challenges in treating metastatic cancers by enabling targeted systemic delivery of virotherapies. By leveraging a sophisticated mechanism that can precisely target tumors, the approach represents a potential paradigm shift in how aggressive and hard-to-treat cancers might be approached.
These findings are particularly significant given the platform's potential to enhance immune system response while reducing the broader physiological impact typically associated with aggressive cancer treatments. The ability to deliver therapeutic payloads directly to tumor sites could represent a more precise and potentially less harmful treatment methodology.
As Calidi Biotherapeutics continues to develop this platform, the research suggests promising implications for future cancer treatment approaches, potentially offering new hope for patients with metastatic and difficult-to-treat cancer types.
